Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 202

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 202
---
7,912,992 |   -1 |     |             |  12,063,940 |   |
| Accumulated Deficit                                |     |             | (5,795,432 | ) |     |            | (8,049,080 | )(2) |     |             | (13,844,512 | ) |

| (1) | Adjustments include adjustment                                                                                                              
 to the carrying value of notes payable, including recognition of day 1 loss (decrease of $7,351); identification of costs to be             
 recorded against Series A Preferred Stock carrying value (decrease of 89,118); and stock compensation adjustments (increase of $8,009,461). |
| (2) | Adjustments                                                                                                                                 
 include reversal of dividend liability recorded (decrease of $331,059);                                                                     
 identification of deferred IPO costs (decrease of ($55,182);                                                                                
 identification of costs to be recorded against Series A Preferred Stock carrying value (decrease of 89,118);                                
 adjustment to the estimated fair value of warrant liability (increase of $240,930);                                                         
 adjustment to the carrying value of notes payable, including recognition of day 1 loss (increase of $274,048);                              
 and stock compensation adjustments (increase of $8,009,461).                                                                                |

Note 3 – Summary of Significant Accounting Policies

Basis of Presentation

These consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements and disclosures have been prepared using the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).

Basis of Consolidation

The consolidated financial statements have been prepared on a consolidated basis with those of the Company’s wholly-owned subsidiaries, Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.

Reclassifications

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that